Bank of Montreal Can Acquires 82,449 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Bank of Montreal Can increased its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 8.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,077,081 shares of the biopharmaceutical company’s stock after buying an additional 82,449 shares during the period. Bank of Montreal Can owned 0.82% of Dynavax Technologies worth $11,848,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Vanguard Group Inc. lifted its stake in shares of Dynavax Technologies by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 9,402,246 shares of the biopharmaceutical company’s stock valued at $116,682,000 after purchasing an additional 126,458 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Dynavax Technologies by 11.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 95,537 shares of the biopharmaceutical company’s stock valued at $1,186,000 after buying an additional 9,839 shares during the period. Tidal Investments LLC bought a new position in Dynavax Technologies during the first quarter worth about $417,000. Swedbank AB acquired a new position in shares of Dynavax Technologies during the 1st quarter worth about $3,740,000. Finally, Boston Partners bought a new stake in shares of Dynavax Technologies in the 1st quarter valued at about $292,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Price Performance

NASDAQ DVAX opened at $12.86 on Monday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The stock has a market cap of $1.69 billion, a price-to-earnings ratio of 98.93 and a beta of 1.34. The business has a 50 day simple moving average of $11.65 and a 200 day simple moving average of $11.38. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $15.01.

Wall Street Analysts Forecast Growth

DVAX has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and set a $29.00 price objective on shares of Dynavax Technologies in a report on Friday, November 8th. The Goldman Sachs Group decreased their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a report on Thursday, August 8th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.